In the Claims

1-16. (canceled)

17. (Previously presented) An implantable device comprising a coating which comprises a block copolymer, the block copolymer comprising a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block is a poly(fluoroalkene), and

wherein the fluorinated block has repeating units of the following structure:



;

wherein the non-fluorinated block has repeating units of the following structure:



,

wherein R_1 is selected from the group consisting of $-CH_3$, $-CF_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, -phenyl, naphthyl, $-COOR_3$, and $-CONR_3R_4$;

wherein R_2 is selected from the group consisting of –H, $-CH_3$, $-CF_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, -phenyl, and naphthyl; and

wherein R_3 and R_4 are selected from the group consisting of $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, $-CH_2CH_2OH$, and –PEG.

18. (Previously presented) The implantable device of claim 17, wherein the block copolymer has a formula comprising three blocks, the middle block having repeating units of the following structure:



, and the two end blocks having repeating units of the following structure



,

wherein R_1' is selected from the group consisting of -CH_3, -CH_2CH_3, -$CH_2CH_2CH_3$, -$CH_2CH_2CH_2CH_3$, -CH_2CH_2OH, and -PEG, and

wherein R_2 is selected from the group consisting of –H or –CH_3, -CF_3, -CH_2CH_3, -$CH_2CH_2CH_3$, -$CH_2CH_2CH_2CH_3$, -phenyl and naphthyl.

19. (Previously presented) The implantable device of claim 18 wherein R_1' is selected from the group consisting of -CH_3, -CH_2CH_3, -$CH_2CH_2CH_3$, -$CH_2CH_2CH_2CH_3$, -CH_2CH_2OH, and -PEG, and

wherein R_2 is –H or –CH_3.

20. (Previously presented) An implantable device comprising a coating which comprises a block copolymer, the block copolymer comprising a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block is a poly(fluoroalkene), wherein the fluorinated block has repeating units of the following structure:



; and

wherein the non-fluorinated block is a polymer selected from the group consisting of polyesters, polyethers, polyanhydrides, polyglycols, poly(alkylene oxides), polyhydroxyalkanoates, polyphosphazenes, polyurethanes, and a combination thereof.

21. (Previously presented) An implantable device comprising a coating which comprises a block copolymer, the block copolymer comprising a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block is a poly(fluoroalkene) wherein the device is a drug-eluting stent, and wherein the coating further comprises a bioactive agent.

22. (Original) The implantable device of claim 17, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

23. (Original) The implantable device of claim 18, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

24. (Original) The implantable device of claim 19, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

25. (Original) The implantable device of claim 20, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

26. (Previously presented) The implantable device of claim 21, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

27. (Previously presented) The implantable device of claim 22, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-

hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

28. (Previously presented) The implantable device of claim 23, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

29. (Previously presented) The implantable device of claim 24, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

30. (Previously presented) The implantable device of claim 25, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

31. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 16.

32. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 17.

33. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 26.

34. (Withdrawn) A method of treating restenosis or vulnerable plaque,

comprising implanting in a human being in need thereof the implantable device of claim 27.

35. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 28.

36-40 (canceled).